Which patients have the highest cardiovascular risk? A follow-up study from Turkey

Eur J Cardiovasc Prev Rehabil. 2005 Jun;12(3):250-6. doi: 10.1097/00149831-200506000-00011.

Abstract

Background: Recent guidelines target individuals at highest risk as a priority. However, implementation of guidelines even in this group is sub-optimal.

Design: A multicenter, observational follow-up study.

Methods: A total of 5600 consecutive patients > or =55 year with high risk of vascular events were evaluated for risk factors and medication usage and followed for 1 year for primary end-points (death, myocardial infarction, stroke), and secondary end-points (revascularization, hospitalization).

Results: The patients were divided into two groups: those without and with vascular disease. In the first group, mortality at 1 year was significantly higher in those with end organ damage (5.8 versus 2.7%, P=0.005). Similarly, the mortality in patients with known vascular disease (CAD, peripheral vascular disease, ischaemic stroke) was higher in the presence of a previous vascular event (7.8 versus 5.3%, P=0.055, vascular event: non-fatal MI/stroke). The use of antiplatelets, statins, beta-blockers and angiotensin-converting enzyme inhibitors was low and did not improve in the follow-up period. The most important predictors of cardiovascular mortality were the presence of end organ damage [odds ratio (OR) 1.65, P=0.001], pre-existing vascular disease (OR 1.49, P=0.023) and protectively, the consistent use of angiotensin-converting enzyme inhibitors (OR 0.49, P=0.001).

Conclusion: In a high-risk Turkish population, the early mortality and morbidity due to cardiovascular events was unacceptably high and medical treatment inadequate. The presence of end organ damage and a previous vascular event increased the risk even further and should be vigorously questioned. Aggressive lifestyle modification and medical therapy should be instituted in these patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / mortality*
  • Cardiovascular Diseases / therapy
  • Female
  • Follow-Up Studies
  • Hospitalization / statistics & numerical data
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / epidemiology
  • Myocardial Infarction / etiology
  • Myocardial Revascularization
  • Odds Ratio
  • Risk Factors
  • Stroke / epidemiology
  • Stroke / etiology
  • Turkey

Substances

  • Angiotensin-Converting Enzyme Inhibitors